公开(公告)号：US20240009215A1

公开(公告)日：2024-01-11

申请号：US18360909

申请日：2023-07-28

Applicant: Novartis AG

Inventor： Michael Cooke ,  Shailaja Kasibhatla ,  Andrew T. Miller ,  Tom Yao-Hsiang Wu

IPC: A61K31/675 ,  A61P35/04 ,  A61K9/00 ,  A61K9/10 ,  A61K9/19 ,  A61K47/02 ,  A61K47/26 ,  C07K16/28

CPC classification number: A61K31/675 ,  A61P35/04 ,  A61K9/0019 ,  A61K9/10 ,  A61K9/19 ,  A61K47/02 ,  A61K47/26 ,  C07K16/2818

Abstract: The invention provided herein includes pharmaceutical compositions comprising a TLR7 agonist having the structure of Formula (A), aluminum-containing particles, and one or more pharmaceutically acceptable excipient. The invention further provides the use of such compositions in the treatment of solid tumors either alone or in combination with one or more additional pharmaceutical compositions.

公开(公告)号：US11752162B2

公开(公告)日：2023-09-12

申请号：US16614280

申请日：2018-05-17

Applicant: Novartis AG

Inventor： Michael Cooke ,  Shailaja Kasibhatla ,  Andrew T. Miller ,  Tom Yao-Hsiang Wu

IPC: A61P35/04 ,  A61K31/675 ,  A61K9/00 ,  A61K9/10 ,  A61K9/19 ,  A61K47/02 ,  A61K47/26 ,  C07K16/28

CPC classification number: A61K31/675 ,  A61K9/0019 ,  A61K9/10 ,  A61K9/19 ,  A61K47/02 ,  A61K47/26 ,  A61P35/04 ,  C07K16/2818

Abstract: The invention provided herein includes pharmaceutical compositions comprising a TLR7 agonist having the structure of Formula (A), aluminum-containing particles, and one or more pharmaceutically acceptable excipient. The invention further provides the use of such compositions in the treatment of solid tumors either alone or in combination with one or more additional pharmaceutical compositions.

公开(公告)号：US20210187033A1

公开(公告)日：2021-06-24

申请号：US17092107

申请日：2020-11-06

Applicant: NOVARTIS AG

Inventor： Anthony Edward Boitano ,  Michael Cooke ,  Shifeng Pan ,  Peter G. Schultz ,  John Edward Tellew ,  Yongqin Wan ,  Xing Wang

IPC: A61K35/28 ,  A61K38/00 ,  C07D487/04 ,  C12N5/0789 ,  C07D473/34 ,  C07D473/16 ,  C07D495/04 ,  A61K9/00 ,  A61K31/52

Abstract: The present invention relates to compounds and compositions for expanding the number of CD34+ cells for transplantation. The invention further relates to a cell population comprising expanded hematopoietic stem cells (HSCs) and its use in autologous or allogeneic transplantation for the treatment of patients with inherited immunodeficient and autoimmune diseases and diverse hematopoietic disorders to reconstitute the hematopoietic cell lineages and immune system defense.

公开(公告)号：US20210154214A1

公开(公告)日：2021-05-27

申请号：US16614280

申请日：2018-05-17

Applicant: Novartis AG

Inventor： Michael Cooke ,  Shailaja Kasibhatla ,  Andrew T. Miller ,  Tom Yao-Hsiang Wu

IPC: A61K31/675 ,  A61K9/19 ,  A61K9/00 ,  A61P35/04 ,  C07K16/28 ,  A61K47/02 ,  A61K47/26 ,  A61K9/10

Abstract: The invention provided herein includes pharmaceutical compositions comprising a TLR7 agonist having the structure of Formula (A), aluminum-containing particles, and one or more pharmaceutically acceptable excipient. The invention further provides the use of such compositions in the treatment of solid tumors either alone or in combination with one or more additional pharmaceutical compositions.

公开(公告)号：US20170239296A1

公开(公告)日：2017-08-24

申请号：US15409292

申请日：2017-01-18

Applicant: NOVARTIS AG

Inventor： Anthony E. Boitano ,  Michael Cooke ,  Shifeng Pan ,  Peter G. Schultz ,  John Tellew ,  Yongqin Wan ,  Xing Wang

IPC: A61K35/28 ,  A61K9/00 ,  C12N5/0789 ,  A61K31/52

CPC classification number: A61K35/28 ,  A61K9/0019 ,  A61K31/52 ,  A61K38/00 ,  A61K2035/124 ,  C07D473/16 ,  C07D473/34 ,  C07D487/04 ,  C07D495/04 ,  C12N5/0647 ,  C12N2501/38 ,  C12N2501/60

Abstract: The present invention relates to compounds and compositions for expanding the number of CD34+ cells for transplantation. The invention further relates to a cell population comprising expanded hematopoietic stem cells (HSCs) and its use in autologous or allogeneic transplantation for the treatment of patients with inherited immunodeficient and autoimmune diseases and diverse hematopoietic disorders to reconstitute the hematopoietic cell lineages and immune system defense.